OncRef

Clinical Trial: NCT03999710

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Memorial Sloan Kettering Cancer Center
Information Provided By:Memorial Sloan Kettering Cancer Center
Last Update Posted:2026-10-28

Study Overview

Brief Summary

The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

Official Title

Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)

Conditions

Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II, NSCLC, Stage III

Intervention / Treatment

  • Radiation: Radiation Therapy
  • Drug: Durvalumab

Other Study ID Numbers

  • 19-218

Start Date (Actual)

2019-07-19

Primary Completion Date (Actual)

2026-10-20

Study Completion Date (Actual)

2026-10-20

Enrollment (Actual)

61

Study Type

Interventional

Phase

Phase 2